53
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Insulin-Like Growth Factor Binding Proteins: A Structural Perspective

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Insulin-like growth factor binding proteins (IGFBP-1 to -6) bind insulin-like growth factors-I and -II (IGF-I and IGF-II) with high affinity. These binding proteins maintain IGFs in the circulation and direct them to target tissues, where they promote cell growth, proliferation, differentiation, and survival via the type 1 IGF receptor. IGFBPs also interact with many other molecules, which not only influence their modulation of IGF action but also mediate IGF-independent activities that regulate processes such as cell migration and apoptosis by modulating gene transcription. IGFBPs-1 to -6 are structurally similar proteins consisting of three distinct domains, N-terminal, linker, and C-terminal. There have been major advances in our understanding of IGFBP structure in the last decade and a half. While there is still no structure of an intact IGFBP, several structures of individual N- and C-domains have been solved. The structure of a complex of N-BP-4:IGF-I:C-BP-4 has also been solved, providing a detailed picture of the structural features of the IGF binding site and the mechanism of binding. Structural studies have also identified features important for interaction with extracellular matrix components and integrins. This review summarizes structural studies reported so far and highlights features important for binding not only IGF but also other partners. We also highlight future directions in which structural studies will add to our knowledge of the role played by the IGFBP family in normal growth and development, as well as in disease.

          Related collections

          Most cited references121

          • Record: found
          • Abstract: found
          • Article: not found

          A decade of fragment-based drug design: strategic advances and lessons learned.

          Since the early 1990s, several technological and scientific advances - such as combinatorial chemistry, high-throughput screening and the sequencing of the human genome - have been heralded as remedies to the problems facing the pharmaceutical industry. The use of these technologies in some form is now well established at most pharmaceutical companies; however, the return on investment in terms of marketed products has not met expectations. Fragment-based drug design is another tool for drug discovery that has emerged in the past decade. Here, we describe the development and evolution of fragment-based drug design, analyse the role that this approach can have in combination with other discovery technologies and highlight the impact that fragment-based methods have made in progressing new medicines into the clinic.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Molecular interactions of the IGF system.

            The insulin-like growth factor (IGF) system is a complex network of two soluble ligands; several cell surface transmembrane receptors and six soluble high-affinity binding-proteins. The IGF system is essential for normal embryonic and postnatal growth, and plays an important role in the function of a healthy immune system, lymphopoiesis, myogenesis and bone growth among other physiological functions. Deregulation of the IGF system leads to stimulation of cancer cell growth and survival. In order to manipulate the IGF system in the treatment of certain disorders, we must understand the protein-protein interactions at a molecular level. The complex molecular interactions of the ligands and receptors of the IGF system underlie all the biological actions mentioned above and will be the focus of this review.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Optimal isotope labelling for NMR protein structure determinations.

              Nuclear-magnetic-resonance spectroscopy can determine the three-dimensional structure of proteins in solution. However, its potential has been limited by the difficulty of interpreting NMR spectra in the presence of broadened and overlapping resonance lines and low signal-to-noise ratios. Here we present stereo-array isotope labelling (SAIL), a technique that can overcome many of these problems by applying a complete stereospecific and regiospecific pattern of stable isotopes that is optimal with regard to the quality and information content of the resulting NMR spectra. SAIL uses exclusively chemically and enzymatically synthesized amino acids for cell-free protein expression. We demonstrate for the 17-kDa protein calmodulin and the 41-kDa maltodextrin-binding protein that SAIL offers sharpened lines, spectral simplification without loss of information, and the ability to rapidly collect the structural restraints required to solve a high-quality solution structure for proteins twice as large as commonly solved by NMR. It thus makes a large class of proteins newly accessible to detailed solution structure determination.
                Bookmark

                Author and article information

                Journal
                Front Endocrinol (Lausanne)
                Front Endocrinol (Lausanne)
                Front. Endocrin.
                Frontiers in Endocrinology
                Frontiers Research Foundation
                1664-2392
                02 March 2012
                2012
                : 3
                : 38
                Affiliations
                [1] 1simpleThe School of Molecular and Biomedical Science, The University of Adelaide Adelaide, SA, Australia
                [2] 2simpleMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University Parkville, VIC, Australia
                Author notes

                Edited by: Michael Lawrence, The Walter and Eliza Hall Institute of Medical Research, Australia

                Reviewed by: Emma June Petrie, The University of Melbourne, Australia; John Pintar, Robert Wood Johnson Medical School, USA

                *Correspondence: Briony E. Forbes, The School of Molecular and Biomedical Science, The University of Adelaide, Gate 8 Victoria Drive, Adelaide, 5005 SA, Australia. e-mail: briony.forbes@ 123456adelaide.edu.au

                This article was submitted to Frontiers in Molecular and Structural Endocrinology, a specialty of Frontiers in Endocrinology.

                Article
                10.3389/fendo.2012.00038
                3356058
                22654863
                89ebee97-da23-421a-97d9-c80f480dfe48
                Copyright © 2012 Forbes, McCarthy and Norton.

                This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.

                History
                : 02 January 2012
                : 16 February 2012
                Page count
                Figures: 3, Tables: 2, Equations: 0, References: 124, Pages: 13, Words: 11963
                Categories
                Endocrinology
                Review Article

                Endocrinology & Diabetes
                insulin-like growth factor,igf binding protein,protein structure
                Endocrinology & Diabetes
                insulin-like growth factor, igf binding protein, protein structure

                Comments

                Comment on this article